QTRX — Quanterix Corporation

Quanterix Corporation (QTRX) Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenue: $43.9 million, up 25% year-over-year and 7% sequentially.
• Organic Revenue: Declined by 22%.
• Diagnostics Revenue: $3.1 million, with a total of $9.6 million from 25 partnerships in 2025, up from $6 million in 2024.
• Simoa Product Revenue: $27 million, down 22% year-over-year.
• Spatial Product Revenue: $17 million, down 23% year-over-year (16% decline excluding a terminated agreement).
• Gross Profit: $20 million (45.7% margin); non-GAAP gross profit of $21.9 million (50% margin).
• Operating Expenses: $44.8 million, with non-GAAP expenses at $37 million, reflecting a $1.5 million decrease sequentially.
• Adjusted EBITDA: Loss of $7.9 million, improved from a loss of $11.9 million in Q3.
• Cash Position: Ended the quarter with $122 million in cash and equivalents.

2. Strategic Updates and Business Highlights

• Leadership Change: Everett Cunningham, with extensive experience in healthcare and diagnostics, is now President and CEO, focusing on growth and operational efficiency.
• Product Development: Launched 13 new assays in 2025, with plans for continuous quarterly launches in 2026.
• Alzheimer's Diagnostics: Achieved significant milestones with the LucentAD complete test, including a reimbursement rate approval of $897 and a 510(k) submission to the FDA.
• Cost Synergies: Implemented $74 million of the $85 million cost synergy target, expected to be fully realized by Q1 2026.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Expected between $169 million to $174 million, with a minimal impact from the terminated diagnostics agreement.
• Gross Margin Expectations: GAAP gross margin projected between 45% to 49%, and non-GAAP gross margin between 49% to 53%.
• Cash Flow Breakeven: Anticipated in the second half of 2026, with an expected cash balance of approximately $100 million by year-end.

4. Bad News, Challenges, or Points of Concern

• Organic Revenue Decline: Significant decline in organic revenue, particularly in the Simoa and Spatial product lines.
• Market Conditions: No expected improvement in academic or pharmaceutical end markets, which could hinder growth.
• Dependency on Partnerships: Continued reliance on diagnostics partnerships for revenue growth, which may pose risks if partnerships do not yield expected results.

5. Notable Q&A Insights

• Strategic Focus: Cunningham emphasized the need to assess and potentially adjust the company's diversified strategy, particularly in high sensitivity proteomics and Spatial Biology.
• Investment in Alzheimer's Diagnostics: Plans to invest in building a sales force and infrastructure to support the LucentAD complete test, while still aiming for breakeven.
• FDA Submission Timeline: Expecting FDA approval for LucentAD complete within 6 to 9 months, with a focus on payer engagement and clinical utility studies to support market entry.
• Accelerator Lab Demand: Strong demand in Q4 for lab services, with a goal to secure larger projects with pharmaceutical partners moving forward.

Overall, while Quanterix demonstrated revenue growth and strategic advancements, it faces challenges with declining organic revenue and market conditions that could impact future performance.